Jonathan Van-Tam on COVID’s Next Phase - Takeaway - MDSpire
Commentary & Perspectives

Jonathan Van-Tam on COVID’s Next Phase

Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19

Share

  • 1

    Sir Jonathan Van-Tam was the Deputy Chief Medical Officer during the pandemic.

  • 2

    Nuvaxovid is a recombinant protein-based COVID-19 vaccine.

  • 3

    COVID-19 is now considered a public health concern similar to seasonal flu.

  • 4

    Diverse vaccine technologies are essential for effective public health responses.

  • 5

    Vaccine acceptance may improve with non-mRNA options.

  • 6

    The aging population presents challenges for vaccination strategies.

  • 7

    Continued research opportunities exist with multiple vaccine platforms.

Original Source(s)

Jonathan Van-Tam on COVID’s Next Phase

  • by James Strachan, Julian Upton

  • April 14, 2026

Related Content

Expanding Access to TB Testing

WHO recommends near point-of-care tests, tongue swabs, and pooling strategies

  • April 14, 2026

  • 2 min
Antivirals Linked to Lower Hospitalization in Influenza

Matched cohort study in nonhospitalized patients

Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness

Comprehensive review highlights label-free viral detection – and the hurdles to real-world deployment

  • April 13, 2026

  • 2 min